Cannabinoid receptor ligands and uses thereof

Details Cannabinoid receptor ligands and uses thereof Cannabinoid receptor ligands and uses thereof

2006-12-05

2006-12-05

Owens, Amelia A. (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S303000

Reexamination Certificate

active

07145012

ABSTRACT:
Compounds of Formula (I) and (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein

REFERENCES:
patent: 3340269 (1967-09-01), Blatter
patent: 3365459 (1968-01-01), Blatter
patent: 3423414 (1969-01-01), Blatter
patent: 3526633 (1970-09-01), Gadekar et al.
patent: 4490541 (1984-12-01), Ellingsfeld et al.
patent: 4925846 (1990-05-01), Deacon et al.
patent: 4944790 (1990-07-01), Moser et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5744491 (1998-04-01), Boigegrain et al.
patent: 5744493 (1998-04-01), Boigegrain et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6100259 (2000-08-01), Xiang et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6355631 (2002-03-01), Achard et al.
patent: 6432984 (2002-08-01), Barth et al.
patent: 6476060 (2002-11-01), Lange et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 6566356 (2003-05-01), Achard et al.
patent: 2001/0027193 (2001-10-01), Achard et al.
patent: 2001/0053788 (2001-12-01), Lange et al.
patent: 2002/0019383 (2002-02-01), Achard et al.
patent: 2002/0019421 (2002-02-01), Biberman et al.
patent: 2002/0035102 (2002-03-01), Achard et al.
patent: 2002/0091114 (2002-07-01), Plot-Grosjean et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2002/0128302 (2002-09-01), Maruani et al.
patent: 2002/0188007 (2002-12-01), Barth et al.
patent: 2003/0003145 (2003-01-01), Abramovici et al.
patent: 2003/0055033 (2003-03-01), Achard et al.
patent: 2003/0114495 (2003-06-01), Finke et al.
patent: 2003/0139386 (2003-07-01), Cote et al.
patent: 2003/0199536 (2003-10-01), Thomas et al.
patent: 2004/0072833 (2004-04-01), Nakai et al.
patent: 2004/0077650 (2004-04-01), Dow
patent: 2004/0092520 (2004-05-01), Griffith
patent: 2004/0122074 (2004-06-01), Dow et al.
patent: 2004/0157838 (2004-08-01), Griffith
patent: 2004/0157839 (2004-08-01), Griffith
patent: 2004/0214837 (2004-10-01), Griffith et al.
patent: 2004/0214838 (2004-10-01), Carpino et al.
patent: 2004/0214856 (2004-10-01), Carpino et al.
patent: 2004/0224970 (2004-11-01), Smith et al.
patent: 4208535 (1992-03-01), None
patent: 293220 (1994-08-01), None
patent: 1162196 (2000-12-01), None
patent: 1354884 (2003-10-01), None
patent: WO 9501980 (1994-06-01), None
patent: WO 96/02248 (1996-02-01), None
patent: WO 9946267 (1999-09-01), None
patent: WO 0063208 (2000-04-01), None
patent: WO 00/15609 (2000-05-01), None
patent: WO 01/24798 (2001-04-01), None
patent: WO 01/028557 (2001-04-01), None
patent: WO 01/029007 (2001-04-01), None
patent: WO 01/032629 (2001-05-01), None
patent: WO 01/032663 (2001-05-01), None
patent: WO 01/58450 (2001-08-01), None
patent: WO 0158869 (2001-08-01), None
patent: WO 01/85092 (2001-11-01), None
patent: WO 02053565 (2002-07-01), None
patent: WO 03007945 (2002-07-01), None
patent: WO 03027114 (2002-09-01), None
patent: WO 02/076949 (2002-10-01), None
patent: WO 03/006007 (2003-01-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/018060 (2003-03-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 03/020314 (2003-03-01), None
patent: WO 03/026647 (2003-04-01), None
patent: WO 03/026648 (2003-04-01), None
patent: WO 03/027069 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/027114 (2003-04-01), None
patent: WO 03/040107 (2003-05-01), None
patent: WO 03/051850 (2003-06-01), None
patent: WO 03/051851 (2003-06-01), None
patent: WO 03/075660 (2003-09-01), None
patent: WO 03/077847 (2003-09-01), None
patent: WO 03/078413 (2003-09-01), None
patent: WO 03/082190 (2003-10-01), None
patent: WO 03/082191 (2003-10-01), None
patent: WO 03/082256 (2003-10-01), None
patent: WO 03/082833 (2003-10-01), None
patent: WO 03/084943 (2003-10-01), None
patent: WO 03/086288 (2003-10-01), None
patent: WO 03/087037 (2003-10-01), None
patent: WO 03095455 (2003-11-01), None
patent: WO 04/012617 (2004-02-01), None
Barth, F et al ‘The developent of cannabinid antagonists’ PubMed ID 10469889 (1999).
Duplantier, AJ et al ‘7-oxo-4,5,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as Novel Inhibitors of Human Eosinophil Phosphodiesterase’ CA 129:49198 (1998).
Ciba Ltd. ‘1H- and 2H-Pyraxolo[3,4-c]pyridine derivatives’ CA 65:12344 (1965).
Duplantier, AJ ‘Preparation of tetrahydropyrazolo[3,4-c]pyridines as inhibitors of phosphodiesteras IV or the production of tumor necrosis factor’ CA 122:239696 (1995).
Black, SC, Cannabinoid receptor antagonists and obesity, PMID:15134279 (2004).
Grigg, R., et al.,Tetrahedron Letters, “A Catalytic Hydrogenation Route to Azomethine Imines”, vol. 31, vol. 31, pp. 2767-2770 (1990).
Kanyonyo, M., et al.,Bioorganic&Medicinal Chemistry Letters, vol. 9, pp. 2233-2236 (1999).
Pertwee, R.,Exp. Opin. Invest. Drugs, “Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development”, vol. 9(7), pp. 1553-1571 (2000).
Tzavara, E.T., et al., “The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for Therapeutic Actions,”J Pharmacol, 138, 544-553 (2003).
Racz, I., et al., “A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking,”J Neurosci, 23(6), 2453-2458 (2003).
Croci, T., et al., “Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor-α in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents,”Brit J Pharmacol, 140, 115-122 (2003).
DaSilva, G.E., et al., “Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats,”Neurosci Let, 349, 49-52 (2003).
Wang, L., et al., “Endocannabinoid Signaling via Cannabinoid Receptor 1 is Involved in Ethanol Preference and its Age-Dependent Decline in Mice,”PNAS, 100(3), 1393-1398 (2003).
Ruiu, S., et al., “Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor,”J Pharmacol Exp Therap, 306, 363-370 (2003).
Howlett, A.C., et al., “International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors,”Pharmacol Rev, 54, 161-202 (2002).
Gomez, R., et al., “A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding,”J. Neurosci, 22(21), 9612-9617 (2002).
Wiley, J.L., et al., “Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation,”J Pharmacol Exp Therap, 296(3), 1013-1022 (2001).
Lellemand, F., et al., “Effects of CB1 Cannabinoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration,”Alcohol Clin Exp Res, 25(9), 1317-1323 (2001).
Pertwee, R.G., “Cannabinoids and the Gastronintestinal Tract,”Gut, 48, 859-867 (2001).
Pertwee, R.G., “Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development,”Exp. Opin. Invest. Drugs, 9(7), 1573-1571 (2000).
Hungund, B.L and B.S. Basavarajappa, “Are Anadamide and Cannabinoid Receptors involved in Ethanol Tolerance? A Review of the Evidence,”Alcohol&Alcoholism. 35(2) 126-133, (2000).
Freedland, C.S., et al., “Effects of SR141716A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding,”Pharmacol Biochem Behav, 67, 265-270 (2000).
Lan, R., et al., “Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists”J. Med. Che.m, 42, 769-776 (1999).
Pertwee, R.G., “Pharmacology of C

Affiliated with

Also associated with

Rating

Cannabinoid receptor ligands and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cannabinoid receptor ligands and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cannabinoid receptor ligands and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3693516